本帖最后由 老马 于 2013-3-13 13:43 编辑 , T% w2 O1 t0 X; {5 j: B' g7 [ L
8 G) \& M+ c; D: U2 s
健择(吉西他滨)+顺铂+阿瓦斯汀
* W4 g/ E+ f, a, \0 p Gemzar +Cisplatin + Avastin
* e: M U* `( @/ `6 _; shttp://annonc.oxfordjournals.org/content/21/9/1804.full9 m l) N' z3 n" Z. g
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) " U6 z, n9 ~; o) }# q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 8 c. }2 J; E' i
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ; n# n1 Z8 {+ g2 O6 v D
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 898)
4 e' N; D( Z. H" {1 u& N
华为网盘附件:. u% a Z; p6 k8 c
【华为网盘】ava.JPG
5 k; V) n4 p0 H |